Related Experiment Video
Updated: May 11, 2026
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Optimal Timing of Dupilumab Application in CRSwNP: Impact of "Neoadjuvant Therapy" on Surgical Outcomes at 1 Year
Weiqing Wang1, Tianhui Kang1, Zhenzhen Zhu1
1Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Key Points:
Preoperative neoadjuvant dupilumab (two doses) combined with full-house endoscopic sinus surgery (ESS) eliminates polyp recurrence at 12 months versus 50% recurrence in ESS-only cohort. Dupilumab-ESS cohort showed superior objective outcomes but comparable subjective symptom relief in this pilot study. "Neoadjuvant therapy" may reduce long-term biologic dependency and costs, while enabling sustained control with topical corticosteroids postoperatively.
